New House Oversight Panel Chairman Towns Less Combative With Industry
This article was originally published in The Tan Sheet
Executive Summary
Drug companies likely will face less combative investigations into their activities by the House Oversight and Government Reform Committee during the 111th Congress
You may also be interested in...
FDA Feels Heat Alongside J&J As House Oversight Investigates OTC Recall
FDA finds itself under congressional scrutiny alongside Johnson & Johnson even as the agency investigates and weighs possible enforcement against J&J following the firm's third OTC recall in eight months
Experts See Food Safety Legislation Taking Back Seat In New Congress
Food safety legislation has only a middling chance of passing Congress in 2009, despite persistent concerns about food supply contamination, according to industry experts
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.